FUNGY

FungY is a Swiss biotechnology startup, spun out from the University of Zurich, dedicated to developing novel antifungal therapies to combat the rising threat of drug-resistant fungal infections. The company utilizes a proprietary discovery platform to identify and optimize fungal-derived compounds and synthetic analogs that target unique pathways in fungal pathogens. Their lead programs focus on treating life-threatening invasive fungal infections, such as candidiasis and aspergillosis, which currently have limited treatment options. By leveraging deep expertise in fungal biology and medicinal chemistry, FungY aims to provide next-generation solutions for patients with compromised immune systems.